We need you! Join our contributor community and become a WikEM editor through our open and transparent promotion process.
SGLT-2 Inhibitor
From WikEM
Revision as of 03:15, 18 April 2017 by Carpenj (Talk | contribs) (Created page with "==Administration== *Type: Diabetes medication *Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes ==...")
Contents
Administration
- Type: Diabetes medication
- Canagliflozin (Invokana), Dapagliflozin (Farxiga), empagliflozin (Jardiance) are FDA approved for use in type 2 diabetes
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Euglycemic DKA[1]
Common
- UTI
- Genital candidiasis
- Weight loss
- Dehydration/Orthostasis
Mechanism of Action
- Inhibit sodium-glucose cotransporter 2, decreasing glucose reabsorption in the proximal tubule
References
- ↑ FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
